2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

153 Post- kidney transplant outcomes in a contemporary cohort of patients with plasma cell disorders and  end-stage kidney disease: A multicenter cohort study

Divya Ravi, N/A, Krishna Chaitanya Allam, BMsc2, Gaddiel Omar Ahmed, MS3, Rosemary Attieh, MD4, Christopher Blosser5, Erica Campagnaro, MD6, Jalal Dildar, MD7, Sami Elrazky, N/A8, Zain El-amir, MD9, Emelia Farnam10, Prakash Gudsoorka, MD11, Hani Hassoun, MD12, Heather J. Landau, MD13, Matthew J. Pianko, MD14, Allison Webber, MD15, Naoka Murakami, MD16, Sabine Karam, MD17
1 University of California, San Francisco, San Francisco, California, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 Ponce Health Sciences University, Ponce, Puerto Rico, United States
4 Mayo Clinic, Jacksonville, Florida, United States
5 University of Washington, Seattle, Washington, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 University of Washington, Seattle, Washington, United States
9 University of Michigan, Ann Arbor, Michigan, United States
10 University of Michigan, Ann Arbor, Michigan, United States
11 University of Cincinnati, Cincinnati, Ohio, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 University of Michigan, Ann Arbor, Michigan, United States
15 University of California, San Francisco, San Francisco, California, United States
16 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
17 University of Minnesota, Minneapolis, Minnesota, United States

BACKGROUND

Kidney transplantation (KTx) is increasingly performed for patients with plasma cell disorders (PCD) and end-stage kidney disease, yet contemporary post-transplant outcomes data in the era of new therapies remain incompletely characterized. Additionally, the clinical trajectory of referred PCD patients who are ultimately not transplanted remains poorly defined.

METHODS

From a retrospective multicenter cohort, approved by each center's institutional review board, of 172 adults with PCD (multiple myeloma [MM], AL amyloidosis, or monoclonal gammopathy of renal significance [MGRS]) referred for KTx evaluation across 6 US academic centers between 2014 and 2025, 53 transplanted and 119 non-transplanted patients were analyzed separately. A modified Charlson comorbidity index (mCCI) omitting the renal-disease and primary PCD components was derived from a 16-item checklist. Deep hematologic response was defined as ≥VGPR, assessed at the time of transplant for post-KTx analyses. Post-KTx endpoints included Kaplan-Meier patient and death-censored graft survival, cumulative incidence of graft failure with death as a competing risk, and recurrence-free survival based on serial monoclonal protein assessments (3 months through 5 years). Non-KTx mortality was analyzed as cause-specific cumulative incidence from referral with a Cox model using mCCI and a gamma frailty term for center.

RESULTS

The transplanted cohort (n=53; MM 39, AL amyloidosis 9, MGRS entities 8) had a median age of 58 years; 39.6% were female, and 62.7% had undergone prior autologous stem-cell transplant (ASCT). Pre-referral therapy included proteasome inhibitors (71.7%), and immunomodulatory agents (35.8%), and anti-CD38 antibodies (18.6%). Donor source was, living in 44.2% and deceased in 55.8%. Median time from referral to transplant was 23.1 months. 

At a median follow-up of 37.0 months, Kaplan-Meier patient survival was 100% at 12 months, 88.3% (95% CI 78.2–99.9%) at 36 months, and 80.7% (95% CI 67.7–96.2%) at 60 months. Overall death-censored graft survival was 96.2%; both graft failures occurred in rare MGRS-spectrum subtypes, while MM and AL amyloidosis each maintained 100% graft survival. Living-donor recipients had lower mortality than deceased-donor recipients (4.5% vs. 24.1%; log-rank P=0.048). Among 8 post-KTx deaths, infection/sepsis predominated (n=4); 1 death (12.5%) was attributed to PCD progression. Biopsy-proven acute rejection occurred in 9.4%, and 34.0% received post-KTx maintenance PCD-directed therapy.

Among 31 patients evaluable for monoclonal protein recurrence, 11 events (34.4%) were detected. Among patients with deep hematologic response at KTx, recurrence was detected in only 16.7% (4/24), compared with 100% (2/2) of those without deep response (log-rank P=0.006), though the non-deep-response group comprised only 2 evaluable patients. This persisted after restricting to patients with at least 1 year of potential follow-up (n=26, 10 events). Patient survival by subtype was 82.1% for MM (7 deaths; 33.1 months follow-up), 88.9% for AL amyloidosis (1 death; 62.3 months), and 100% for MGRS entities (0 deaths; 29.7 months).

Among 83 non-transplanted patients with documented follow-up, cumulative incidence of death was 6.2% at 20 months, 20.6% at 40 months, and 24.4% at 60 months from referral. Notably, zero non-transplant deaths were attributable to PCD progression (0/14), replicating across all subtypes; predominant causes were infection/sepsis (6/14) and cardiovascular disease (2/14). The mCCI predicted non-KTx mortality (HR 1.57, 95% CI 1.01–2.45; P=0.047), stable across leave-one-center-out re-estimation (HR range 1.35–1.71).

CONCLUSIONS

Post-KTx outcomes were favorable, with 80.7% five-year patient survival; graft failures were confined to rare MGRS-spectrum subtypes, with MM and AL amyloidosis achieving 100% graft survival. Among all the variables evaluated, only donor-type and deep hematologic responses at KTx were significantly associated with recurrence-free survival. Among non-transplanted patients, mortality was driven exclusively by non-PCD causes — predominantly infection and cardiovascular disease — while 1 of 8 post-KTx deaths was PCD-attributable, a divergence that may reflect immunosuppression effects on disease biology and warrants prospective investigation. Comorbidity burden predicted non-transplant mortality, reinforcing its role as the central modifiable risk factor across the transplant evaluation continuum.

Sabine Karam, MD: No relevant conflicts of interest to declare.